191 related articles for article (PubMed ID: 37435077)
1. Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes.
Karapetyan L; AbuShukair HM; Li A; Knight A; Al Bzour AN; MacFawn IP; Thompson ZJ; Chen A; Yang X; Dadey R; Karunamurthy A; De Stefano DV; Sander C; Kunning SR; Najjar YG; Davar D; Luke JJ; Gooding W; Bruno TC; Kirkwood JM; Storkus WJ
Front Immunol; 2023; 14():1171978. PubMed ID: 37435077
[TBL] [Abstract][Full Text] [Related]
2. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma.
Lynch KT; Young SJ; Meneveau MO; Wages NA; Engelhard VH; Slingluff CL; Mauldin IS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103353
[TBL] [Abstract][Full Text] [Related]
4. Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients.
Huang B; Han W; Sheng ZF; Shen GL
Cancer Cell Int; 2020; 20():195. PubMed ID: 32508531
[TBL] [Abstract][Full Text] [Related]
5. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
Li X; Wan Z; Liu X; Ou K; Yang L
Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma.
Xu W; Ma C; Liu W; Anwaier A; Tian X; Shi G; Qu Y; Wei S; Zhang H; Ye D
Cancer Immunol Immunother; 2022 Aug; 71(8):1923-1935. PubMed ID: 35043231
[TBL] [Abstract][Full Text] [Related]
7. The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.
Wang B; Liu J; Han Y; Deng Y; Li J; Jiang Y
Front Immunol; 2022; 13():868155. PubMed ID: 35664009
[TBL] [Abstract][Full Text] [Related]
8. Analysis on tumor immune microenvironment and construction of a prognosis model for immune-related skin cutaneous melanoma.
Wu M; Wang Z; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):671-681. PubMed ID: 37539569
[TBL] [Abstract][Full Text] [Related]
9. Integrative lactylation and tumor microenvironment signature as prognostic and therapeutic biomarkers in skin cutaneous melanoma.
Zhu Y; Song B; Yang Z; Peng Y; Cui Z; Chen L; Song B
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17897-17919. PubMed ID: 37955686
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Jung HH; Kim JY; Cho EY; Lee JE; Kim SW; Nam SJ; Park YH; Ahn JS; Im YH
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958571
[TBL] [Abstract][Full Text] [Related]
11. Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma.
Fan Y; Liang X; Yu D
Aging (Albany NY); 2021 Oct; 13(19):23036-23071. PubMed ID: 34613934
[TBL] [Abstract][Full Text] [Related]
12. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
13. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.
Ukita M; Hamanishi J; Yoshitomi H; Yamanoi K; Takamatsu S; Ueda A; Suzuki H; Hosoe Y; Furutake Y; Taki M; Abiko K; Yamaguchi K; Nakai H; Baba T; Matsumura N; Yoshizawa A; Ueno H; Mandai M
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35552285
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
15. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
16. Genomic properties and clinical outcomes associated with tertiary lymphoid structures in patients with breast cancer.
Wang L; Gong S; Pang L; Zhang S; Zhang X; He W
Sci Rep; 2023 Aug; 13(1):13542. PubMed ID: 37598257
[TBL] [Abstract][Full Text] [Related]
17. The Role of CXCL13 and CXCL9 in Early Breast Cancer.
Razis E; Kalogeras KT; Kotsantis I; Koliou GA; Manousou K; Wirtz R; Veltrup E; Patsea H; Poulakaki N; Dionysopoulos D; Pervana S; Gogas H; Koutras A; Pentheroudakis G; Christodoulou C; Linardou H; Pavlakis K; Koletsa T; Pectasides D; Zagouri F; Fountzilas G
Clin Breast Cancer; 2020 Feb; 20(1):e36-e53. PubMed ID: 31699671
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract][Full Text] [Related]
19. The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma.
Tamiya Y; Nakai T; Suzuki A; Mimaki S; Tsuchihara K; Sato K; Yoh K; Matsumoto S; Zenke Y; Nosaki K; Izumi H; Shibata Y; Sakai T; Taki T; Miyazaki S; Watanabe R; Sakamoto N; Sakashita S; Kojima M; Hashimoto N; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2022 Dec; 174():125-132. PubMed ID: 36379125
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
